Definition
The first antiretroviral drug regimen used to treat a previously treatment-naïve HIV-infected patient.
Introduction
Although there are many possible choices for initial antiretroviral therapy (ART) in an HIV-infected patient, only a small subset of the potential options are now recommended in treatment guidelines used in most resource-rich settings. Recommendations are based on a combination of efficacy, safety, tolerability, convenience, and in some cases cost. This review will focus primarily on regimens recommended and used in the United States, where cost has traditionally not been a criterion for guideline selection. However, that may change as less expensive generic drugs become available.
US guidelines include those from the Department of Health and Human Services (DHHS), which are updated approximately once a year (Panel on Antiretroviral Guidelines for Adults and Adolescents 2015), and those from the International Antiviral Society (IAS-USA), updated every 2 years...
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Cahn P, Andrade-Villanueva J, Arribas JR, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naïve adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014;14:572–80.
Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222–31.
Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65:e121–4.
Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer for atazanavir plus emtricitabine/tenofovir DF in treatment-naïve HIV-1-infected patients: Week 48 results. J Infect Dis. 2013;208:32–9.
Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312:1–17.
Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014;161:461–71.
Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0. Accessed 1 June 2015.
Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942–51.
Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204:1191–201.
Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–18.
Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results [letter]. J Acquir Immune Defic Syndr. 2014;65:3118–21.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media LLC
About this entry
Cite this entry
Gallant, J. (2018). Initial Antiretroviral Regimens. In: Hope, T.J., Richman, D.D., Stevenson, M. (eds) Encyclopedia of AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-7101-5_445
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7101-5_445
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-7100-8
Online ISBN: 978-1-4939-7101-5
eBook Packages: MedicineReference Module Medicine